This lesson highlights the objectives for this course.
Chemotherapy_Induced Peripheral Neuropathy (CIPN) typically starts in the hands and/or feet. Often times the symptoms reported are that of numbness and tingling but can progress to shooting and burning pain with increased sensitivity to temperature. Chemotherapy-Induced Peripheral Neuropathy is one of the most common reasons why cancer patients discontinue treatment. In this course we’ll take a look at this malady and give you information and tools to ensure that the patients you take care receive the best care possible.
Upon completion of this course you will be able to:
- Gain a better understanding of the Nervous System
- Understand the types of medications that commonly cause CIPN
- Understand how to perform an initial CIPN screening
- Articulate common sense procedures that facilities and providers often follow in order to align with HIPAA requirements
- Understand the penalties and consequences of failure to follow HIPAA guidelines
- Know what you, as a health and human services worker, must do to protect people’s privacy
Course Instructor Profile: Rochelle Lonn BSN, RN, OCN
Rochelle Lonn received her Bachelors of Science in Nursing at California State University, Stanislaus in 2008 and joined the UC Davis Betty Irene Moore School of Nursing Masters of Science program in 2013. Since obtaining her Bachelors in Nursing, Rochelle has worked as an Oncology nurse at an acute care facility. She further specialized her knowledge in this field by obtaining her Oncology Nurse Certification in 2008. Rochelle has recently been promoted to Assistant Nurse Manager of Oncology Services at Sutter Health- Memorial Medical Center in Modesto. This position entails managing a 27 bed inpatient Medical-Surgical Oncology unit, Palliative Care program, IV Therapy Services, Nurse Navigation program, Cancer Research program and Cancer Registry.
- CA Board of Registered Nursing: CA Provider # CEP 15849
- District of Columbia Board of Nursing: CE Provider #50-14108
- California Board of Vocational Nursing Provider # V10810
- Psychiatric Technicians Provider # V10806
- DSS/CCL Division for Adult Residential Facilities (ARF) Vendor Approval # 2000149-735-2: Course Approval #149-0112-25078
- DSS/CCL Division for Residential Facilities for the Elderly (RCFE) Vendor Approval # 2000149-740-2: Course Approval #149-0112-25079
- DSS/CCL Division for Group Homes (GH) Vendor Approval # 2000149-730-2: Course Approval #149-0112-25081
Far Northern Regional Center
- Coriat R, Alexandre J, Nicco C, et al Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. J Clin Invest. 2014 Jan 2;124(1):262-72.
- Loprinzi CL, Qin R, Dakhil SR, et al. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). J Clin Oncol. 2013 Dec 2.
- Paice JA. Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs. 2009 May;25(2 Suppl 1):S8-19.
- Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol. 2008: Vol 26 No 15S 1040.
- Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-inducedperipheral neuropathy. Am J Health Syst Pharm. 2014 Jan 1;71(1):19-25.
This lesson introduces the course on CIPN
This lesson gives a review of the nervous system.
This lesson covers medication considerations that need to be taken into account.
This lesson highlights patient considerations.
In this lesson the fundamentals of performing an initial CIPN screening will be performed.
This lesson takes you right to the bedside to watch how seasoned nurse and oncology interact during a CIPN assessment. After completing this lesson take the final quiz and get…